Skip to main content

Sodium polystyrene sulfonate and Alcohol/Food Interactions

There are 3 alcohol/food/lifestyle interactions with sodium polystyrene sulfonate.

Moderate

Sodium Polystyrene Sulfonate Multivitamins With Minerals

Moderate Drug Interaction

ADJUST DOSING INTERVAL: Simultaneous administration of cation-donating preparations may reduce the potassium exchange capability of cation-exchange resins due to binding of the cation to the resin.

MANAGEMENT: Patients should consider separating the times of administration of the cation-exchange resin and any cation-donating preparation (e.g., mineral supplements; antacids; products containing antacids such as didanosine buffered tablets or pediatric oral solution) by several hours if possible.

References

  1. (2001) "Product Information. Kayexalate (sodium polystyrene sulfonate)." Sanofi Winthrop Pharmaceuticals
  2. (2002) "Product Information. Resonium Calcium (calcium polystyrene sulfonate)." Sanofi-Synthelabo Canada Inc

Switch to consumer interaction data

Moderate

Sodium Polystyrene Sulfonate Food

Moderate Food Interaction

GENERALLY AVOID: Potassium in foods can bind to the cation exchange resin and interfere with potassium removal in the treatment of hyperkalemia.

MANAGEMENT: Cation exchange resins should not be mixed with orange juice or other foods with a high potassium content.

ADJUST DOSING INTERVAL: Cation exchange resins may bind to other medications that are administered orally. Reduced systemic absorption and therapeutic efficacy may occur. Manufacturers have reported that polystyrene sulfonate exchange resins can decrease the absorption of lithium and levothyroxine. A more recent study found that sodium polystyrene sulfonate binds to many commonly prescribed oral medications. Another potassium-lowering drug, patiromer, has also been found to bind about half of the medications tested, some of which are commonly used in patients who require potassium-lowering drugs.

MANAGEMENT: To minimize the risk of interaction, patients should be advised to separate the dosing of the cation exchange resin from other orally administered medications by at least 3 hours. The dosing interval should be increased to 6 hours for patients with gastroparesis or other conditions resulting in delayed emptying of food from the stomach into the small intestine. Health care professionals should monitor blood levels and/or clinical response to the other medications when appropriate.

References

  1. (2001) "Product Information. Kayexalate (sodium polystyrene sulfonate)." Sanofi Winthrop Pharmaceuticals
  2. Cerner Multum, Inc. "UK Summary of Product Characteristics."
  3. Cerner Multum, Inc. "Australian Product Information."

Switch to consumer interaction data

Major

Sodium Polystyrene Sulfonate High Blood Pressure (Hypertension)

Major Potential Hazard, Moderate plausibility

sodium polystyrene sulfonate - sodium load

The use of sodium polystyrene sulfonate is associated with an elevation in sodium. Therapy with sodium polystyrene sulfonate should be administered cautiously in patients with conditions that might be exacerbated by additional sodium such as severe congestive heart failure, severe hypertension, or marked edema. Compensatory restriction of sodium intake from other sources may be indicated.

References

  1. (2001) "Product Information. Kayexalate (sodium polystyrene sulfonate)." Sanofi Winthrop Pharmaceuticals
  2. Meyer I (1993) "Sodium polystyrene sulfonate: a cation exchange resin used in treating hyperkalemia." ANNA J, 20, p. 93-5

Sodium polystyrene sulfonate drug interactions

There are 128 drug interactions with sodium polystyrene sulfonate.

Sodium polystyrene sulfonate disease interactions

There are 3 disease interactions with sodium polystyrene sulfonate which include:


Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.